RU2017115563A - Композиции и способы лечения дисфункции мейбомиевых желез - Google Patents
Композиции и способы лечения дисфункции мейбомиевых желез Download PDFInfo
- Publication number
- RU2017115563A RU2017115563A RU2017115563A RU2017115563A RU2017115563A RU 2017115563 A RU2017115563 A RU 2017115563A RU 2017115563 A RU2017115563 A RU 2017115563A RU 2017115563 A RU2017115563 A RU 2017115563A RU 2017115563 A RU2017115563 A RU 2017115563A
- Authority
- RU
- Russia
- Prior art keywords
- composition
- administration
- patient
- keratolytic agent
- selenium disulfide
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/327—Peroxy compounds, e.g. hydroperoxides, peroxides, peroxyacids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/02—Medicinal preparations containing materials or reaction products thereof with undetermined constitution from inanimate materials
- A61K35/04—Tars; Bitumens; Mineral oils; Ammonium bituminosulfonate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
- A61K8/22—Peroxides; Oxygen; Ozone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
- A61K8/23—Sulfur; Selenium; Tellurium; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Inorganic Chemistry (AREA)
- Ophthalmology & Optometry (AREA)
- Birds (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Emergency Medicine (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Claims (30)
1. Способ лечения дисфункции мейбомиевых желез у пациента, нуждающегося в этом, включающий местное введение пациенту композиции, которая достигает края века пациента, при этом композиция содержит терапевтически эффективное количество по меньшей мере одного кератолитического средства в офтальмически приемлемом носителе.
2. Способ по п. 1, в котором кератолитическим средством является пероксид бензоила, каменноугольный деготь, дитранол, салициловая кислота, селена дисульфид, альфа-гидроксикислота, мочевина, молочная кислота, тиогликолят натрия, пиритион цинка или L-пирролидон карбоксилат цинка.
3. Способ по п. 2, в котором кератолитическим средством является салициловая кислота или селена дисульфид.
4. Способ по п. 3, в котором кератолитическим средством является селена дисульфид.
5. Способ по п. 4, в котором концентрация селена дисульфида в композиции составляет от около 0,1% до около 10%.
6. Способ по п. 3, в котором кератолитическим средством является салициловая кислота.
7. Способ по п. 6, в котором концентрация салициловой кислоты в композиции составляет от около 0,1% до около 10%.
8. Способ по п. 1, в котором композицию вводят местным путем пациенту до тех пор, пока не будет облегчена кератиновая обструкция.
9. Способ по п. 1, в котором композицию вводят местным путем пациенту периодически после облегчения кератиновой обструкции.
10. Способ по п. 1, в котором местное введение является однократным введением.
11. Способ по п. 1, при котором местное введение является периодическим введением.
12. Способ по п. 11, в котором периодическое введение осуществляют один раз в сутки.
13. Способ по п. 11, в котором периодическое введение осуществляют два раза в сутки.
14. Способ по п. 1, в котором композиция для местного введения является полутвердой.
15. Способ по п. 1, в котором композиция для местного введения является гомогенной.
16. Способ по п. 1, в котором композиция для местного введения является дисперсией.
17. Способ по п. 1, в котором композиция для местного введения является гидрофильной.
18. Способ по п. 1, в котором композиция для местного введения имеет масляную основу.
19. Способ по п. 1, в котором офтальмически приемлемый носитель содержит по меньшей мере одно офтальмически приемлемое вспомогательное средство.
20. Способ по п. 1, в котором введение композиции приводит к повышенной секреции мейбомиевых желез.
21. Способ лечения дисфункции мейбомиевых желез у пациента, нуждающегося в этом, включающий местное введение пациенту композиции, которая достигает края века пациента, при этом композиция состоит из терапевтически эффективного количества кератолитического средства в офтальмически приемлемом носителе.
22. Способ по п. 21, в котором кератолитическим средством является салициловая кислота или селена дисульфид.
23. Способ по п. 22, в котором кератолитическим средством является селена дисульфид.
24. Способ по п. 23, в котором концентрация селена дисульфида в композиции составляет от около 0,1% до около 10%.
25. Способ по п. 21, в котором введение композиции приводит к повышенной секреции мейбомиевых желез.
26. Способ по п. 21, в котором композиция для местного введения является гомогенной.
27. Способ по п. 21, в котором композиция для местного введения является дисперсией.
28. Способ по п. 21, в котором композиция для местного введения является гидрофильной.
29. Способ по п. 21, в котором композиция для местного введения имеет масляную основу.
30. Способ по п. 21, в котором офтальмически приемлемый носитель содержит по меньшей мере одно офтальмически приемлемое вспомогательное средство.
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462065716P | 2014-10-19 | 2014-10-19 | |
| US62/065,716 | 2014-10-19 | ||
| US14/732,622 | 2015-06-05 | ||
| US14/732,622 US9463201B2 (en) | 2014-10-19 | 2015-06-05 | Compositions and methods for the treatment of meibomian gland dysfunction |
| PCT/IB2015/002164 WO2016063130A1 (en) | 2014-10-19 | 2015-10-16 | Compositions and methods for the treatment of meibomian gland dysfunction |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| RU2017115563A true RU2017115563A (ru) | 2018-11-20 |
| RU2017115563A3 RU2017115563A3 (ru) | 2019-02-14 |
| RU2730464C2 RU2730464C2 (ru) | 2020-08-24 |
Family
ID=55748155
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2017115563A RU2730464C2 (ru) | 2014-10-19 | 2015-10-16 | Композиции и способы лечения дисфункции мейбомиевых желез |
Country Status (23)
| Country | Link |
|---|---|
| US (9) | US9463201B2 (ru) |
| EP (2) | EP3206497B1 (ru) |
| JP (4) | JP6799532B2 (ru) |
| KR (2) | KR102350869B1 (ru) |
| CN (2) | CN107105669B (ru) |
| AU (2) | AU2015334586B2 (ru) |
| BR (1) | BR112017007975A2 (ru) |
| CA (1) | CA2964685A1 (ru) |
| CY (1) | CY1123821T1 (ru) |
| DK (1) | DK3206497T3 (ru) |
| ES (1) | ES2848102T3 (ru) |
| HR (1) | HRP20210085T1 (ru) |
| HU (1) | HUE053485T2 (ru) |
| IL (2) | IL251724B (ru) |
| LT (1) | LT3206497T (ru) |
| MX (2) | MX2017005030A (ru) |
| PL (1) | PL3206497T3 (ru) |
| PT (1) | PT3206497T (ru) |
| RS (1) | RS61295B1 (ru) |
| RU (1) | RU2730464C2 (ru) |
| SI (1) | SI3206497T1 (ru) |
| SM (1) | SMT202100242T1 (ru) |
| WO (1) | WO2016063130A1 (ru) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9642520B2 (en) | 2009-04-01 | 2017-05-09 | Tearscience, Inc. | Background reduction apparatuses and methods of ocular surface interferometry (OSI) employing polarization for imaging, processing, and/or displaying an ocular tear film |
| US8092023B2 (en) | 2009-04-01 | 2012-01-10 | Tearscience, Inc. | Ocular surface interferometry (OSI) methods for imaging and measuring ocular tear film layer thickness(es) |
| US9888839B2 (en) | 2009-04-01 | 2018-02-13 | Tearscience, Inc. | Methods and apparatuses for determining contact lens intolerance in contact lens wearer patients based on dry eye tear film characteristic analysis and dry eye symptoms |
| US9724230B2 (en) | 2012-01-04 | 2017-08-08 | Sight Sciences, Inc. | Dry eye treatment apparatus and methods |
| US9510972B2 (en) | 2012-01-04 | 2016-12-06 | Sight Sciences, Inc. | Dry eye treatment systems |
| US10973680B2 (en) | 2012-01-04 | 2021-04-13 | Sight Sciences, Inc. | Controller for dry eye treatment systems |
| US9339177B2 (en) | 2012-12-21 | 2016-05-17 | Tearscience, Inc. | Full-eye illumination ocular surface imaging of an ocular tear film for determining tear film thickness and/or providing ocular topography |
| CN105792729B (zh) | 2013-05-03 | 2018-04-27 | 眼泪科学公司 | 用于对睑板腺进行成像以供睑板腺分析的眼睑照明系统和方法 |
| US9795290B2 (en) | 2013-11-15 | 2017-10-24 | Tearscience, Inc. | Ocular tear film peak detection and stabilization detection systems and methods for determining tear film layer characteristics |
| WO2016022066A1 (en) | 2014-08-04 | 2016-02-11 | Jerry Tan Eye Surgery Pte Ltd | Pharmaceutical compositions for demodex related blepharitis and eyelid crusting |
| US9463201B2 (en) | 2014-10-19 | 2016-10-11 | M.G. Therapeutics Ltd | Compositions and methods for the treatment of meibomian gland dysfunction |
| WO2017024032A2 (en) | 2015-08-03 | 2017-02-09 | Enb Therapeutics, Llc | Compositions and methods for treating cancers associated with etbr activation |
| CN108472312A (zh) | 2015-09-28 | 2018-08-31 | 阿祖拉眼科有限公司 | 用于增加睑板腺脂质分泌物的含硫醇及二硫化物的药剂 |
| US11040062B2 (en) * | 2016-04-14 | 2021-06-22 | Azura Ophthalmics Ltd. | Selenium disulfide compositions for use in treating meibomian gland dysfunction |
| AU2017252026A1 (en) | 2016-04-19 | 2018-11-08 | Azura Ophthalmics Ltd. | Compositions for the treatment of hyperkeratosis disorders |
| EP3600272A4 (en) * | 2017-03-29 | 2021-01-13 | Azura Ophthalmics Ltd. | AGENTS FOR INCREASING THE SECRETION OF THE LIPID GLANDS OF MEIBOMIUS |
| ES2955561T3 (es) | 2017-05-05 | 2023-12-04 | Craig Litherland | Dispositivos para el tratamiento de párpados |
| US11759472B2 (en) | 2017-11-21 | 2023-09-19 | Cs Pharmaceuticals Limited | Compositions and methods of use for treating aberrant inflammation in peri-ocular secretory glands or at the ocular surface |
| KR102712798B1 (ko) | 2017-11-21 | 2024-10-04 | 씨에스 파마슈티컬스 리미티드 | 안구주위 분비선 또는 안구 표면에서의 이상 염증을 치료하기 위한 조성물 및 사용 방법 |
| SI3723739T1 (sl) | 2017-12-15 | 2024-08-30 | Tarsus Pharmaceuticals, Inc. | Paraziticidni pripravki na osnovi izoksazolina in njihova uporaba za zdravljenje blefaritisa |
| AU2019206652B2 (en) | 2018-01-12 | 2024-11-14 | Enb Therapeutics, Inc. | Deuterated compounds, compositions, and methods for treating cancers associated with ETBR activation |
| WO2019175290A1 (en) | 2018-03-13 | 2019-09-19 | Beckley Canopy Therapeutics Limited | Cannabis or cannabis derived compositions for promoting cessation of chemical dependence |
| US12263115B2 (en) | 2018-09-11 | 2025-04-01 | Sight Sciences, Inc. | Forceps treatment systems |
| US12502377B2 (en) | 2019-04-04 | 2025-12-23 | Tarsus Pharmaceuticals, Inc. | Method of eradicating ticks that attach to humans using lotilaner formulations |
| JP7723603B2 (ja) * | 2019-04-12 | 2025-08-14 | アズーラ オフサルミックス エルティーディー． | コンタクトレンズ不快感を処置するための組成物および方法 |
| JP2022529315A (ja) | 2019-04-18 | 2022-06-21 | アズーラ オフサルミックス エルティーディー． | 眼障害を処置するための化合物および方法 |
| JP7700045B2 (ja) | 2019-04-18 | 2025-06-30 | アズーラ オフサルミックス エルティーディー． | 眼障害を処置するための化合物および方法 |
| WO2021026154A1 (en) * | 2019-08-05 | 2021-02-11 | Sight Sciences, Inc. | Controller with imaging system |
| CA3160069A1 (en) * | 2019-11-04 | 2021-05-14 | Azura Ophthalmics Ltd. | Metered dose for disorders in or around the eye |
| CN114980895A (zh) * | 2019-11-04 | 2022-08-30 | 阿祖拉眼科有限公司 | 针对蠕形螨及其相关病症的计量剂量 |
| JP2023513415A (ja) | 2020-01-02 | 2023-03-31 | アズーラ オフサルミックス エルティーディー． | 二硫化セレン組成物の製造 |
| JP7796016B2 (ja) * | 2020-01-10 | 2026-01-08 | アズーラ オフサルミックス エルティーディー． | 組成物および過敏症のための指示 |
| US20210308154A1 (en) | 2020-03-24 | 2021-10-07 | Hovione Scientia Limited | Methods and Compositions for Treating Meibomian Gland Dysfunction |
| US20230399317A1 (en) * | 2020-10-21 | 2023-12-14 | Azura Ophthalmics Ltd. | Compounds and methods for the treatment of ocular disorders |
| US11459351B1 (en) | 2021-04-05 | 2022-10-04 | Azura Ophthalmics Ltd. | Compounds and methods for the treatment of ocular disorders |
| WO2022269348A1 (en) * | 2021-06-24 | 2022-12-29 | Azura Ophthalmics Ltd. | Compositions and methods for vision improvement |
| WO2024100454A2 (en) * | 2022-11-11 | 2024-05-16 | Azura Ophthalmics Ltd. | Composition and methods for improving signs and symptoms of ocular disorders |
| WO2025012701A2 (en) * | 2023-07-07 | 2025-01-16 | Azura Ophthalmics Ltd. | Administration of keratolytics to ocular and periocular surfaces |
Family Cites Families (96)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3236730A (en) | 1962-01-04 | 1966-02-22 | Miles Lab | Blepharitis composition comprising antiseptic, quaternary ammonium compound, keratolytic agent and a chelating compound |
| US5602130A (en) | 1987-03-20 | 1997-02-11 | Allergan | Disubstituted acetylenes bearing heteroaromatic and heterobicyclic groups having retinoid like activity |
| US5645827A (en) * | 1992-09-30 | 1997-07-08 | Union Carbide Chemicals & Plastics Technology Corporation | Muco-adhesive polymers |
| CN1050748C (zh) * | 1993-04-22 | 2000-03-29 | 孟丽君 | 表面麻醉涂膜剂的制备方法 |
| JP2891883B2 (ja) | 1993-11-05 | 1999-05-17 | 学校法人近畿大学 | 抗白内障医薬組成物 |
| FR2728163A1 (fr) | 1994-12-20 | 1996-06-21 | Oreal | Composition cosmetique, dermatologique ou pharmaceutique stable contenant du disulfure de selenium et au moins un sel de zinc |
| WO1997020578A1 (en) | 1995-12-04 | 1997-06-12 | University Of Miami | Non-preserved topical corticosteroid for treatment of dry eye, filamentary keratitis, and delayed tear clearance |
| US5965606A (en) | 1995-12-29 | 1999-10-12 | Allergan Sales, Inc. | Methods of treatment with compounds having RAR.sub.α receptor specific or selective activity |
| EP0930072A1 (en) | 1998-01-13 | 1999-07-21 | Kartar Dr. Lalvani | Vitamin and mineral containing compositions for the treatment of dry eye |
| JP3407654B2 (ja) | 1998-04-14 | 2003-05-19 | ライオン株式会社 | 眼科用組成物 |
| US6348508B1 (en) | 2000-04-04 | 2002-02-19 | Bausch & Lomb Incorporated | Method for treating dry eye |
| US8512718B2 (en) | 2000-07-03 | 2013-08-20 | Foamix Ltd. | Pharmaceutical composition for topical application |
| FR2832637B1 (fr) | 2001-06-07 | 2004-07-30 | Lefaix Marie Therese Droy | Utilisation d'un antioxydant pour la fabrication d'un medicament destine au traitement des affections oculaires de surface |
| SI1441734T1 (sl) | 2001-10-26 | 2007-08-31 | Angeletti P Ist Richerche Bio | Dihidropirimidin karboksamidni inhibitorji HIV-integraze |
| FR2833268B1 (fr) | 2001-12-12 | 2005-07-08 | Fabre Pierre Dermo Cosmetique | Nouvelle association contenant un poloxamer et de l'acide chondroitine sulfurique et/ou une glycoproteine et son utilisation |
| KR100564386B1 (ko) * | 2002-05-13 | 2006-03-27 | 주식회사 마이코플러스 | 4-하이드록시-5-메톡시-4-[2-메틸-3-(3-메틸-2-부테닐)-2-옥시란닐]-1-옥사스피로[2,5]옥탄-6-온을 함유한 지루치료용 약제학적 조성물 |
| US8420699B1 (en) | 2002-06-19 | 2013-04-16 | Irvine L. Dubow | Composition and methods of treatment using deionized and ozonated solution |
| EP2319493A3 (en) | 2002-07-23 | 2011-07-27 | Novartis AG | Ophthalmic ointment composition comprising a drug, an ointment base and a solubilizing/dispersing agent |
| CA2496005C (en) | 2002-08-19 | 2013-07-23 | Ira Sanders | Use of botulinum toxin for the treatment of fine wrinkles and pore size |
| US20040171561A1 (en) * | 2002-09-03 | 2004-09-02 | Popp Karl F. | Topical formulations for treatment of rosacea |
| JP2006504701A (ja) | 2002-09-30 | 2006-02-09 | マーク・エー・バビザイェフ | 眼疾患の局所的治療方法、並びに、その治療用組成物及び治療用手段 |
| US20060188471A1 (en) * | 2002-10-31 | 2006-08-24 | Podolsky Daniel K | Methods of treating epithelial lesions |
| GB0225795D0 (en) | 2002-11-05 | 2002-12-11 | Guillon Michael | Wipes |
| US20070269537A1 (en) * | 2003-02-10 | 2007-11-22 | Bioderm Research | Skin Condition Improvement Including Acne, Rosacea, and Topical Wounds by Artemisia Annua Extract via Iron Siderophore Trojan Horse Delivery System |
| GB0322448D0 (en) | 2003-09-25 | 2003-10-29 | Lamellar Therapeutics Ltd | Using lamellar bodies to modify linear biological macro molecules |
| JP2007517893A (ja) | 2004-01-10 | 2007-07-05 | バイオリピッド インコーポレイテッド | 脂質組成物及び該脂質組成物の使用方法 |
| GB0404693D0 (en) | 2004-03-02 | 2004-04-07 | Univ London | Pharmaceutical preparations for the treatment of ocular surface and other disorders |
| US20050197614A1 (en) | 2004-03-04 | 2005-09-08 | Wilson Pritchard | Occlusive biomedical devices, punctum plugs, and methods of use thereof |
| US20050202097A1 (en) | 2004-03-12 | 2005-09-15 | Melbj Holdings, Llc, Florida | Lubricant for the ocular surface |
| US8455016B2 (en) * | 2004-03-12 | 2013-06-04 | Melbj Holdings, Llc | Treatment for meibomian gland dysfunction or obstruction |
| EP2255832A3 (en) | 2004-06-16 | 2011-02-09 | Affinergy, Inc. | IFBM's to promote attachment of target analytes |
| EP1621191A1 (en) | 2004-07-29 | 2006-02-01 | Werner Bollag | Treatment of inflammatory diseases by RXR Antagonists |
| WO2006119174A1 (en) | 2005-04-30 | 2006-11-09 | Ocular Surface Center, P.A. | Method for treating ocular demodex |
| RU2008102249A (ru) | 2005-06-22 | 2009-07-27 | Кова Компани, Лтд. (Jp) | Профилактический или терапевтичесский агент для корнеального /конъюнктивального заболевания |
| US20070016256A1 (en) | 2005-07-18 | 2007-01-18 | Korb Donald R | Method and apparatus for treating gland dysfunction |
| WO2013003594A2 (en) | 2011-06-28 | 2013-01-03 | Tearscience, Inc. | Methods and systems for treating meibomian gland dysfunction using radio-frequency energy |
| US7981095B2 (en) | 2005-07-18 | 2011-07-19 | Tearscience, Inc. | Methods for treating meibomian gland dysfunction employing fluid jet |
| US20070166402A1 (en) | 2005-12-12 | 2007-07-19 | Friedlaender Mitchell H | Compositions, methods and kits for removing debris from an ocular area |
| RU2314102C1 (ru) * | 2006-04-07 | 2008-01-10 | Федеральное государственное учреждение "МОСКОВСКИЙ НАУЧНО-ИССЛЕДОВАТЕЛЬСКИЙ ИНСТИТУТ ГЛАЗНЫХ БОЛЕЗНЕЙ имени ГЕЛЬМГОЛЬЦА ФЕДЕРАЛЬНОГО АГЕНТСТВА ПО ЗДРАВООХРАНЕНИЮ И СОЦИАЛЬНОМУ РАЗВИТИЮ" | Способ комплексного лечения дисфункции мейбомиевых желез |
| EP2677039B8 (en) | 2006-05-10 | 2022-10-05 | DxTerity Diagnostics Incorporated | Detection of nucleic acid targets using chemically reactive oligonucleotide probes |
| US8568790B2 (en) | 2006-05-31 | 2013-10-29 | Medihoney Pty Ltd. | Medicinal compositions containing honey |
| US20080021068A1 (en) * | 2006-07-24 | 2008-01-24 | Akorn, Inc. | Aqueous gel formulation and method for inducing topical anesthesia |
| US20090123527A1 (en) * | 2006-07-24 | 2009-05-14 | Akorn, Inc. | Method of inducing topical anesthesia and transdermal patch |
| WO2008027069A1 (en) * | 2006-08-21 | 2008-03-06 | Tearscience, Inc. | Method and apparatus for treating meibomian gland dysfunction employing fluid |
| US8249695B2 (en) * | 2006-09-29 | 2012-08-21 | Tearscience, Inc. | Meibomian gland imaging |
| US8090426B2 (en) | 2006-10-27 | 2012-01-03 | Felder Robin A | Microelectronic biosensor plug |
| US20100204317A1 (en) * | 2006-11-03 | 2010-08-12 | Qlt Inc. | Methods of treating dermatological disorders or conditions |
| JP4987078B2 (ja) | 2006-11-30 | 2012-07-25 | 株式会社メニコン | 眼科用組成物 |
| AU2008219600A1 (en) * | 2007-02-28 | 2008-09-04 | Aciex Therapeutics, Inc. | Methods and compositions for normalizing meibomian gland secretions |
| WO2008116029A1 (en) | 2007-03-19 | 2008-09-25 | Wisconsin Alumni Research Foundation | Modulation of bacterial quorum sensing with synthetic ligands |
| US8128968B2 (en) | 2007-08-29 | 2012-03-06 | Tissuetech, Inc. | Compositions and methods for treating Demodex infestations |
| CA3014633C (en) | 2007-10-08 | 2022-05-17 | Aurinia Pharmaceuticals Inc. | Ophthalmic compositions comprising calcineurin inhibitors or mtor inhibitors |
| EP2285346A1 (en) | 2008-03-26 | 2011-02-23 | Eric Donnenfeld | Methods for improving lid margin and tear film function and treatment of lid margin desease using tetracycline family antibiotics |
| CN102105137B (zh) | 2008-04-30 | 2015-01-07 | Qlt股份有限公司 | 复合泪管植入物及相关方法 |
| AU2009268549B2 (en) | 2008-07-10 | 2015-07-16 | Allergan, Inc. | Cyclosporin derivatives for treating ocular and dermal diseases and conditions |
| CA2737475A1 (en) | 2008-09-19 | 2010-03-25 | Alacrity Biosciences, Inc. | Tetracycline stabilizing formulations |
| US9888839B2 (en) | 2009-04-01 | 2018-02-13 | Tearscience, Inc. | Methods and apparatuses for determining contact lens intolerance in contact lens wearer patients based on dry eye tear film characteristic analysis and dry eye symptoms |
| PL2424374T3 (pl) | 2009-05-01 | 2018-07-31 | Advanced Vision Research, Inc. | Kompozycje środka oczyszczającego i metody jego stosowania |
| WO2011006079A2 (en) | 2009-07-10 | 2011-01-13 | Lyotropoic Therapeutics, Inc. | Ophthalmic formulations of reversed liquid crystalline phase materials and methods of using |
| CN101612161A (zh) * | 2009-08-07 | 2009-12-30 | 魏谠全 | 一种眼药组合物及其制剂 |
| CN102038953B (zh) * | 2009-10-14 | 2012-07-18 | 上海昊海生物科技股份有限公司 | 一种眼科手术前局部麻醉用组合物及其制备方法和用途 |
| WO2011053801A2 (en) | 2009-10-30 | 2011-05-05 | Intratus, Inc. | Methods and cosmetic preparations for the sustained delivery of therapeutic agents to the eye |
| EP2506843A4 (en) | 2009-12-02 | 2013-04-17 | Bridge Pharma Inc | TREATMENT OF THE DRY EYE WITH COMPOUNDS TO INCREASE MOMENTUM DRY SECRETION |
| US8791158B2 (en) | 2010-01-11 | 2014-07-29 | Gtx, Inc. | Methods of treating meibomian gland dysfunction |
| CN106137528B (zh) * | 2010-03-31 | 2020-12-01 | 奥库杰克特有限责任公司 | 用于眼内药物递送的设备和方法 |
| DE102010026696A1 (de) * | 2010-07-06 | 2012-01-12 | Nadja Knop | Fettstift zur medizinischen Applikation von Wirkstoffen auf den Rand des Augenlides |
| US8304840B2 (en) | 2010-07-29 | 2012-11-06 | Taiwan Semiconductor Manufacturing Company, Ltd. | Spacer structures of a semiconductor device |
| US20120093876A1 (en) | 2010-10-13 | 2012-04-19 | Aciex, Inc. | Ophthalmic Formulations, Methods Of Manufacture And Methods of Normalizing Meibomian Gland Secretions |
| CN103249429A (zh) | 2010-11-08 | 2013-08-14 | 希尔洛有限公司 | 缓冲的眼用组合物以及使用其的方法 |
| EP2654741A1 (en) * | 2010-12-22 | 2013-10-30 | Galderma Research & Development | Modulators and methods for the treatment of rosacea |
| JP5952302B2 (ja) | 2010-12-29 | 2016-07-13 | ニチャミン、ルイス・ディー | 眼の治療のための方法及びキット |
| US20130281390A1 (en) | 2010-12-29 | 2013-10-24 | Kurt E. Brubaker | Method for treating dry eye |
| WO2012092378A1 (en) | 2010-12-29 | 2012-07-05 | Inspire Pharmaceuticals, Inc. | Method for treating blepharitis |
| UA114705C2 (uk) * | 2011-01-26 | 2017-07-25 | Аллерган, Інк. | Андрогенна композиція для лікування офтальмологічного захворювання |
| US20150038473A1 (en) * | 2011-05-12 | 2015-02-05 | Foresight Biotherapeutics, Inc. | Stable povidone-iodine compositions with steroids or non-steroidal anti-inflammatories |
| CA2835816A1 (en) | 2011-05-20 | 2012-11-29 | Keio University | Novel metalloprotein and process for producing same, and prophylactic or therapeutic agent for corneal and conjunctival diseases comprising said metalloprotein |
| CA2840626A1 (en) | 2011-06-29 | 2013-01-03 | Insite Vision Incorporated | Methods of treating recurrent meibomian glands disorder and thereby decreasing the frequency of recurrence |
| ITFI20120044A1 (it) | 2012-03-01 | 2013-09-02 | Biodue Spa | Formulazione ad uso oftalmico comprendente olio di jojoba. |
| WO2013156493A1 (en) | 2012-04-16 | 2013-10-24 | Lipotec S.A. | Compounds for the treatment and/or care of the skin and/or mucous membranes and their use in cosmetic or pharmaceutical compositions |
| EP2664330A1 (de) | 2012-05-15 | 2013-11-20 | F. Holzer GmbH | Zusammensetzung und Arzneimittel enthaltend Omega-3-Fettsäuren sowie einen Glucosaminoglucan |
| JP2015537009A (ja) | 2012-11-20 | 2015-12-24 | リバイブ・セラピューティクス・インコーポレイテッド | 痛風の治療におけるブシラミンの使用 |
| US9211397B2 (en) | 2012-12-19 | 2015-12-15 | Senju Usa, Inc. | Patch for treatment of eyelid disease containing clobetasol |
| EP2948130B1 (en) | 2013-01-24 | 2019-03-13 | Rigel Pharmaceuticals, Inc. | Composition for ophthalmic administration |
| RU2687275C2 (ru) * | 2013-02-01 | 2019-05-13 | Аллерган, Инк. | Слезозаменитель, содержащий гиалуронат натрия и карбоксиметилцеллюлозу |
| US9987235B2 (en) | 2013-08-01 | 2018-06-05 | Nicholas L. Abbott | Methods and compositions for modifying mucous membranes |
| PL3033336T3 (pl) | 2013-08-14 | 2018-11-30 | Kalvista Pharmaceuticals Limited | Inhibitory kalikreiny w plaźmie |
| RS59383B1 (sr) | 2014-05-07 | 2019-11-29 | Croma Pharma Ges M B H | Vodeni oftalmološki rastvor i postupak za lečenje sindroma suvog oka |
| EP3151827B1 (en) | 2014-06-04 | 2024-12-18 | Tersus Pharmaceuticals, LLC | Methods of treating chronic dry eye disease using c16:1n7 palmitoleate and derivatives thereof |
| US9463201B2 (en) | 2014-10-19 | 2016-10-11 | M.G. Therapeutics Ltd | Compositions and methods for the treatment of meibomian gland dysfunction |
| WO2016066195A1 (en) | 2014-10-29 | 2016-05-06 | Laboratoire Medidom Sa | Heat-sterilized formulation comprising chitosan and process of preparation thereof |
| JPWO2016140242A1 (ja) | 2015-03-03 | 2018-02-01 | 日油株式会社 | 点眼剤 |
| CN108472312A (zh) | 2015-09-28 | 2018-08-31 | 阿祖拉眼科有限公司 | 用于增加睑板腺脂质分泌物的含硫醇及二硫化物的药剂 |
| CN105456287B (zh) | 2015-12-03 | 2017-06-30 | 大有药业扬州有限公司 | 二硫化硒超微粉体及其制备方法 |
| US11040062B2 (en) | 2016-04-14 | 2021-06-22 | Azura Ophthalmics Ltd. | Selenium disulfide compositions for use in treating meibomian gland dysfunction |
| AU2017252026A1 (en) | 2016-04-19 | 2018-11-08 | Azura Ophthalmics Ltd. | Compositions for the treatment of hyperkeratosis disorders |
| JP7723603B2 (ja) | 2019-04-12 | 2025-08-14 | アズーラ オフサルミックス エルティーディー． | コンタクトレンズ不快感を処置するための組成物および方法 |
-
2015
- 2015-06-05 US US14/732,622 patent/US9463201B2/en active Active
- 2015-10-16 PT PT158520866T patent/PT3206497T/pt unknown
- 2015-10-16 PL PL15852086T patent/PL3206497T3/pl unknown
- 2015-10-16 DK DK15852086.6T patent/DK3206497T3/da active
- 2015-10-16 BR BR112017007975A patent/BR112017007975A2/pt not_active Application Discontinuation
- 2015-10-16 RU RU2017115563A patent/RU2730464C2/ru active
- 2015-10-16 EP EP15852086.6A patent/EP3206497B1/en active Active
- 2015-10-16 CN CN201580069536.1A patent/CN107105669B/zh active Active
- 2015-10-16 SI SI201531506T patent/SI3206497T1/sl unknown
- 2015-10-16 KR KR1020217014908A patent/KR102350869B1/ko active Active
- 2015-10-16 JP JP2017520877A patent/JP6799532B2/ja active Active
- 2015-10-16 EP EP20208119.6A patent/EP3831396A1/en active Pending
- 2015-10-16 WO PCT/IB2015/002164 patent/WO2016063130A1/en not_active Ceased
- 2015-10-16 CA CA2964685A patent/CA2964685A1/en active Pending
- 2015-10-16 SM SM20210242T patent/SMT202100242T1/it unknown
- 2015-10-16 RS RS20210003A patent/RS61295B1/sr unknown
- 2015-10-16 AU AU2015334586A patent/AU2015334586B2/en active Active
- 2015-10-16 HR HRP20210085TT patent/HRP20210085T1/hr unknown
- 2015-10-16 ES ES15852086T patent/ES2848102T3/es active Active
- 2015-10-16 MX MX2017005030A patent/MX2017005030A/es unknown
- 2015-10-16 LT LTEP15852086.6T patent/LT3206497T/lt unknown
- 2015-10-16 KR KR1020177013487A patent/KR102255726B1/ko active Active
- 2015-10-16 CN CN202110190118.5A patent/CN112972682A/zh active Pending
- 2015-10-16 HU HUE15852086A patent/HUE053485T2/hu unknown
-
2016
- 2016-09-19 US US15/269,833 patent/US10034887B2/en active Active
-
2017
- 2017-04-13 IL IL251724A patent/IL251724B/en active IP Right Grant
- 2017-04-18 MX MX2021001439A patent/MX2021001439A/es unknown
-
2018
- 2018-06-26 US US16/019,253 patent/US10588915B2/en active Active
-
2019
- 2019-09-05 US US16/562,374 patent/US10772899B2/en active Active
-
2020
- 2020-03-03 AU AU2020201548A patent/AU2020201548A1/en not_active Abandoned
- 2020-06-05 JP JP2020098624A patent/JP2020169181A/ja active Pending
- 2020-07-02 US US16/919,749 patent/US11013749B2/en active Active
-
2021
- 2021-01-17 IL IL280209A patent/IL280209A/en unknown
- 2021-01-18 CY CY20211100035T patent/CY1123821T1/el unknown
- 2021-04-21 US US17/236,258 patent/US11633410B2/en active Active
-
2023
- 2023-01-10 JP JP2023001954A patent/JP2023062705A/ja active Pending
- 2023-03-08 US US18/119,251 patent/US12048707B2/en active Active
-
2024
- 2024-06-28 US US18/759,278 patent/US12447162B2/en active Active
- 2024-06-28 US US18/759,260 patent/US12427158B2/en active Active
- 2024-07-05 JP JP2024109118A patent/JP2024150506A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2017115563A (ru) | Композиции и способы лечения дисфункции мейбомиевых желез | |
| EA201792559A1 (ru) | Фармацевтические композиции для местного применения | |
| MX2019015578A (es) | Metodos para tratar la enfermedad de huntington. | |
| EA201992806A1 (ru) | Ингибирование роста кристалла рофлумиласта | |
| MX2019015580A (es) | Metodos para tratar la enfermedad de huntington. | |
| RU2013141845A (ru) | Фармацевтическая композиция в виде крема, содержащая оксиметазолин, для лечения симптомов розацеа | |
| MX2020010300A (es) | Sales monoacidas de 6-aminoisoquinolinas y usos de las mismas. | |
| EA201790088A1 (ru) | Ингибиторы syk | |
| MX361590B (es) | Suministro topico de composiciones para la piel que tienen ph bajo. | |
| MX2024000828A (es) | Formulaciones de parasiticida de isoxazolina y metodos para el tratamiento de la blefaritis. | |
| WO2018111315A8 (en) | PYRIMIDINE TRICYCLIC ENONE DERIVATIVES FOR INHIBITION OF RORγ AND OTHER USES | |
| MX2021010106A (es) | Inhibidores de la via de respuesta al estres integrada. | |
| WO2018005801A3 (en) | Novel non-systemic tgr5 agonists | |
| RU2019139886A (ru) | Терапевтическое средство против дисфункции мейбомиевых желез | |
| MX2019003470A (es) | Composicion farmaceutica y metodo para el tratamiento de la enfermedad del higado graso no alcoholico. | |
| EA201791138A1 (ru) | Фармацевтическая композиция, ее приготовление и применения | |
| BR112015022044A2 (pt) | um método de proporcionar neutroproteção ocular | |
| RU2018107930A (ru) | Агонисты tlr4, их композиции и применение для лечения рака | |
| EA202092472A1 (ru) | Высокомолекулярная гиалуроновая кислота для лечения и предупреждения тяжелого заболевания глазной поверхности | |
| MX2020013692A (es) | Compuestos de pirazol e imidazol para la inhibicion de il-17 y rorgamma. | |
| EA201591653A1 (ru) | Композиции для лечения глазных расстройств с применением дипиридамола | |
| MX2016008546A (es) | Reduccion de queloides utilizando alantoina topica. | |
| MX2023012483A (es) | Formulaciones farmaceuticas transdermicas para el tratamiento del dolor cronico. | |
| MX2022004806A (es) | Metodos y composiciones para tratar la anemia drepanocitica con un inhibidor de la ferroportina (vit-2763). | |
| EA202193211A1 (ru) | Лечение синуклеопатий |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| HZ9A | Changing address for correspondence with an applicant |